- Home
- MNPR vs TKNO Comparison
MNPR vs TKNO Comparison
Compare MNPR & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- TKNO
- Stock Information
- Founded
- MNPR 2014
- TKNO 1996
- Country
- MNPR United States
- TKNO United States
- Employees
- MNPR N/A
- TKNO N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- TKNO Medicinal Chemicals and Botanical Products
- Sector
- MNPR Health Care
- TKNO Health Care
- Exchange
- MNPR Nasdaq
- TKNO Nasdaq
- Market Cap
- MNPR 390.5M
- TKNO 340.9M
- IPO Year
- MNPR 2019
- TKNO 2021
- Fundamental
- Price
- MNPR $86.16
- TKNO $5.25
- Analyst Decision
- MNPR Strong Buy
- TKNO
- Analyst Count
- MNPR 12
- TKNO 0
- Target Price
- MNPR $96.64
- TKNO N/A
- AVG Volume (30 Days)
- MNPR 97.3K
- TKNO 200.8K
- Earning Date
- MNPR 11-10-2025
- TKNO 11-06-2025
- Dividend Yield
- MNPR N/A
- TKNO N/A
- EPS Growth
- MNPR N/A
- TKNO N/A
- EPS
- MNPR N/A
- TKNO N/A
- Revenue
- MNPR N/A
- TKNO $38,923,000.00
- Revenue This Year
- MNPR N/A
- TKNO $9.52
- Revenue Next Year
- MNPR N/A
- TKNO $15.20
- P/E Ratio
- MNPR N/A
- TKNO N/A
- Revenue Growth
- MNPR N/A
- TKNO 11.40
- 52 Week Low
- MNPR $12.55
- TKNO $3.94
- 52 Week High
- MNPR $105.00
- TKNO $10.37
- Technical
- Relative Strength Index (RSI)
- MNPR 57.75
- TKNO 48.26
- Support Level
- MNPR $77.00
- TKNO $5.04
- Resistance Level
- MNPR $89.32
- TKNO $5.67
- Average True Range (ATR)
- MNPR 7.00
- TKNO 0.33
- MACD
- MNPR -1.45
- TKNO -0.06
- Stochastic Oscillator
- MNPR 44.25
- TKNO 35.35
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.